FDA Puts Speed Breaker On Novavax's COVID/Flu Combo Shot Trial On Concerns Related To Damaged Nerves
Portfolio Pulse from Vandana Singh
The FDA has placed a clinical hold on Novavax's COVID-19-influenza combination vaccine trial due to a serious adverse event reported in a participant. This has led to a significant drop in Novavax's stock price.
October 16, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novavax's stock dropped 19% after the FDA placed a clinical hold on its COVID-19-influenza combination vaccine trial due to a serious adverse event. The company is collaborating with the FDA to address the issue.
The FDA's clinical hold on Novavax's trial due to safety concerns is a significant regulatory setback, leading to a sharp decline in NVAX stock. The company's efforts to resolve the issue may mitigate long-term impacts, but short-term investor sentiment is likely negative.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100